Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00272909 · ClinicalTrials.gov registry record · Phase 2
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase 2 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00272909 is a Phase 2 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 43 participants.
The verdict
NCT00272909, a Phase 2 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This research study is designed to evaluate the safety, tolerability, and efficacy of SUN N4057 (piclozotan) in subjects with acute ischemic stroke within 9 hours of the onset of symptoms.
Interventions
- DRUG placebo
- DRUG piclozotan low dose
- DRUG piclozotan high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00272909
The ClinicalTrials.gov registry entry for NCT00272909 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00272909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00272909 about?
NCT00272909 is a clinical study titled "Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)". This research study is designed to evaluate the safety, tolerability, and efficacy of SUN N4057 (piclozotan) in subjects with acute ischemic stroke within 9 hours of the onset of symptoms.
What is the current status of trial NCT00272909?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2004-09. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00272909?
The interventions under investigation include: placebo (DRUG), piclozotan low dose (DRUG), piclozotan high dose (DRUG).
Who is sponsoring clinical trial NCT00272909?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.